Neuraxis announces positive university of michigan ib-stim™ cost effectiveness study at anms 2023

Carmel, ind., aug. 15, 2023 (globe newswire) -- neuraxis, inc. (nyse american: nrxs) (“neuraxis” or the “company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced a poster presentation from the university of michigan that highlighted the cost-effectiveness of its penfs or ib-stim™ therapy in the treatment of irritable bowel syndrome (ibs) in adolescents at the 2023 american neurogastroenterology and motility society (anms) annual meeting in austin, tx.
NRXS Ratings Summary
NRXS Quant Ranking